News from ARMAGEN A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 23, 2014, 07:00 ET
ArmaGen. (PRNewsFoto/ArmaGen)

ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome

 ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies to treat severe neurological disorders,...

Sep 04, 2013, 09:00 ET

ARMAGEN® Expands Patent Portfolio With Issuance Of Two Additional U.S. Patents

ARMAGEN, a leader in the field of transporting therapeutics across the blood brain barrier (BBB) today announced the issuance of two additional...

Jul 18, 2013, 13:22 ET

ARMAGEN® Receives US Orphan Designation For Lead Product AGT-182

 ARMAGEN announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product AGT-182 for...

Jan 03, 2013, 19:14 ET

ArmaGen Technologies, Inc. Hires Biotech Executive as CEO

ArmaGen Technologies, Inc., a leader in the delivery of biotherapeutics targeting the central nervous system (CNS), today announced James Callaway,...

Nov 29, 2012, 19:39 ET

ArmaGen Technologies, Inc. Announces $17 Million Series A Financing

 ArmaGen Technologies, Inc. today announced the closing of a $17 million Series A financing to support the development of brain-penetrating...

Jul 16, 2010, 18:32 ET

ArmaGen® Re-engineers Erythropoietin for Brain Penetration

Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and...